NCT06413810已完成不适用
A Randomised, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of a Food Ingredient on Self-reported Stress in Healthy Adults
Unilever R&D2 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2024年7月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 2
- 主要终点
- Change in Perceived Stress Scale (PSS) Total Score from baseline to end of intervention
研究概览
简要总结
The goal of this study is to investigate if a food ingredient can improve stress in healthy adults who experience moderate symptoms of self-reported stress. The main question it aims to answer is if 4 weeks of daily intake of the ingredient reduces stress compared to 4 weeks of daily intake of a placebo product.
Participants will:
- consume both the test and placebo products for 4-weeks each in a randomised order, with 4 weeks in between
- visit the test site 6 times over the 13 weeks
- complete a series of assessments on stress and sleep quality and provide blood, stool and saliva samples
详细描述
A double-blind, randomised, placebo-controlled, crossover study with 6 visits over 13-weeks. Participants will consume study product or placebo for two 4-week intervention periods.
Primary Objective: To evaluate in healthy adults, experiencing moderate symptoms of self-reported stress, the effect of 4-week daily supplementation of a food ingredient versus placebo on stress.
Secondary Objectives: To evaluate in healthy adults, experiencing moderate symptoms of self-reported stress, the effect of 4-week daily supplementation of a food ingredient versus placebo on:
- Mood
- Plasma GABA levels
- Salivary cortisol awakening response (CAR)
- Acute effects on stress
- Faecal GABA
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •To be eligible for inclusion, the Participant must fulfil all the following criteria:
- •Be able to give written informed consent.
- •Be between 18 and 50 years of age.
- •Has a BMI between ≥ 18.0 and ≤ 30.0 kg/m
- •Have moderate stress, as measured on Cohen's Perceived Stress Scale (PSS), with a score between 14 and 26 (inclusive) at both Screening and Baseline Visits.
- •Is in general good health, as determined by the investigator.
- •Willing to consume the Study Product daily for the duration of the study and comply with the study procedures.
排除标准
- •The presence of any of the following criteria will exclude the Participant from participating in the study:
- •Scores ≥10 on General Anxiety Disorder 7 item (GAD-7) questionnaire.
- •Scores ≥10 Patient Health Questionnaire 9 item (PHQ-9).
- •Participants who are pregnant or wish to become pregnant during the study.
- •Participants who are lactating and/or currently breastfeeding.
- •Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:
- •Complete abstinence from intercourse two weeks prior to administration of the study product, throughout the human study, until the completion of follow-up procedures or for two weeks following discontinuation of the study product in cases where Participant discontinues the study prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).
- •Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that Participant.
- •Sexual partner(s) is/are exclusively female.
- •Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), tubal ligation, or contraceptive pill. The Participant must be using this method for at least one week prior to and one week following the end of the study.
- •Use of any intrauterine device (IUD) or contraceptive implant. The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.
- •Is hypersensitive to any of the components of the Study Product.
- •Have a significant acute or chronic coexisting illness such as such as uncontrolled hypertension, type 1 or 2 diabetes, cardiovascular diseases or any condition which may, in the opinion of the investigator, impact their ability to participate in the study or impact the study outcomes.
- •Use of systemic antibiotics within the 12 weeks prior to Visit
- •Use of systemic immunosuppressant drugs, steroids, etc. within the 12 weeks prior to Visit
- •Participants diagnosed and treated with prescribed medications for anxiety and depression in the 12 weeks prior to Visit
- •Participants who have taken 3 doses laxative or anti-diarrheal medication in the past 12 weeks, at investigator discretion.
- •Herbal treatments for mood disorders or psychological conditions (e.g., valerian, St. John's Wort) within 4 weeks prior to Visit 1 or planning to start during the study period.
- •Disease such as coeliac disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, stomach or duodenal ulcers, gastroesophageal reflux disease (GERD) that by the investigator's judgement, could interfere with the intestinal barrier function or have undergone significant gastrointestinal surgery (appendectomy and cholecystectomy acceptable).
- •Participants consuming prebiotics (containing fructans, galacto-oligosaccharides, psyllium husk, inulin as main component), or probiotics within last 4 weeks prior to Visit
- •Participants consuming GABA or glutamate supplements, or any other supplements that are thought to directly affect digestive health and mental well-being within 4 weeks prior to Visit 1 which in the opinion of the investigator, impact the study outcomes.
- •Participants with a current history of drug (including illicit drug) and /or alcohol abuse at the time of enrolment.
- •Has received treatment involving experimental supplements in the past 4 weeks, at the discretion of the investigator.
- •Major changes in lifestyle (i.e., diet, dieting, exercise level, travelling, supplements) for duration of the study.
- •Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
- •Any Participant who is an employee of the study site or an Atlantia Clinical Trials employee or their immediate family member or a member of their household.
结局指标
主要结局
Change in Perceived Stress Scale (PSS) Total Score from baseline to end of intervention
时间窗: 4 weeks
The PSS is a self-reported measure of stress. The questions in this scale ask about participants feelings and thoughts during the last month. Respondents are asked how often they felt a certain way on a five-point scale from 'never' to 'very often'. It is a 10-item questionnaire and has a total score which correlates with one of three score categories (low stress \[0-13\], moderate stress \[14-26\]and high stress
次要结局
- Plasma GABA levels(4 weeks)
- Salivary cortisol awakening response(4 weeks)
- Profile of Mood States Questionnaire (POMS)(4 weeks)
- VAS scale on acute effects on stress(30 hours)
- Faecal GABA quantification(4 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
The Efficacy of a Probiotic Blend on Stress in Moderately Stressed TeensStressNCT05766306Lallemand Health Solutions30
已完成
Unknown
A study of the effects of test food on stress, sleep quality and fatigue -A randomized, double-blind, placebo-controlled, parallel studyHealthy subjects who are stressed and have problems such as sleep quality or fatigue (Non-chronic, non-illness)JPRN-UMIN000049989Kanyukai clinic52
招募中
不适用
Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome PatientsIrritable Bowel SyndromeNCT06145022Universität Duisburg-Essen118
招募中
不适用
A randomized trial to evaluate effect of mediatation on Stress and Anxiety due to COVID-19 in healthy adult populatioCTRI/2020/08/027035Dr Divya Jain
已完成
不适用
Effects of a Probiotic on Aspects of Mental WellnessMental Health WellnessNCT05905679Fonterra Research Centre120